- Home
- ENLV vs EDIT Comparison
ENLV vs EDIT Comparison
Compare ENLV & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENLV | EDIT |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.3M | 206.0M |
| IPO Year | 2014 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ENLV | EDIT |
|---|---|---|
| Price | $1.14 | $2.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $13.00 | $4.50 |
| AVG Volume (30 Days) | 336.3K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $0.66 | $0.91 |
| 52 Week High | $2.10 | $4.54 |
Technical Indicators
Market Signals| Indicator | ENLV | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 57.00 | 61.72 |
| Support Level | $1.00 | $2.01 |
| Resistance Level | $1.23 | $2.76 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 56.00 | 86.29 |
Price Performance
Historical ComparisonAbout ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.